Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc (NQ: CMND )

0.1659 +0.0134 (+8.79%)
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,802,839
Open 0.1560
Bid (Size) 0.1612 (5)
Ask (Size) 0.1666 (365)
Prev. Close 0.1525
Today's Range 0.1560 - 0.1730
52wk Range 0.1500 - 6.100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death Intellectual Property
Exposures Death Intellectual Property
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $2.25 Million Public Offering for Clearmind Medicine Inc. (NASDAQ:CMND)
Via ACCESSWIRE

Performance

YTD
-94.70%
-94.70%
1 Month
-58.50%
-58.50%
3 Month
-69.84%
-69.84%
6 Month
-92.63%
-92.63%
1 Year
-97.19%
-97.19%

More News

Read More
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
Via Benzinga
Exposures Product Safety
Clearmind Medicine Closes US$2.25 Million Public Offering
From Clearmind Medicine Inc.
Via GlobeNewswire
Psychedelics Capital Moves: Beckley Waves Raises $3.3M, Clearmind's $2.25M Public Offering
Via Benzinga
Nasdaq Surges 100 Points; First Wave BioPharma Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Crude Oil Rises Sharply; BIOLASE Shares Plunge
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Clearmind Medicine Stock Is Getting Hammered Today
Via Benzinga
Dow Jumps Over 200 Points; US Producer Prices Rise In August
Via Benzinga
Topics Stocks
Exposures US Equities
Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering
From Clearmind Medicine Inc.
Via GlobeNewswire
Why Novo Integrated Sciences Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Nasdaq Grants SpiSparc, Ltd. Extension To Maintain Listing: +600% Bid Price Surge Needed
Via Benzinga
Johns Hopkins Will Work With Clearmind On Alcohol Addiction Research Program
Via Benzinga
Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
From SciSparc Ltd
Via GlobeNewswire
EXCLUSIVE: Clearmind Medicine Files US Patent Application For Dyskinesia Treatment, Strengthening Its IP Portfolio
Via Benzinga
Clearmind Medicine Announces Share-Based Payment for the Company's Consultants
From Clearmind Medicine Inc.
Via GlobeNewswire
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
From SciSparc Ltd
Via GlobeNewswire
Exclusive: Clearmind And SciSparc To Conduct Study Evaluating Psychedelics And CannAmide Based Drug For Treatment Of Obesity And Metabolic Syndrome
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.